Valuation Update With 7 Day Price Move • 11h
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩20,100, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 57% over the past three years. Buy Or Sell Opportunity • Jun 19
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 2.8% to ₩18,240. The fair value is estimated to be ₩23,482, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 45% in the next 2 years. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩19,460, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years. Buy Or Sell Opportunity • Jun 02
Now 21% undervalued Over the last 90 days, the stock has risen 5.1% to ₩18,520. The fair value is estimated to be ₩23,482, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 45% in the next 2 years. Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩22,300, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 48% over the past three years. Reported Earnings • Mar 18
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: EPS: ₩1,487 (up from ₩1,382 in FY 2024). Revenue: ₩926.9b (up 14% from FY 2024). Net income: ₩66.0b (up 7.8% from FY 2024). Profit margin: 7.1% (down from 7.5% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 5.4%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 6% per year. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₩22,000, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 41% over the past three years. Announcement • Feb 13
DongKook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2026 DongKook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 715, yeongdong-daero, gangnam-gu, seoul South Korea Declared Dividend • Dec 15
Dividend of ₩200 announced Dividend of ₩200 is the same as last year. Ex-date: 29th December 2025 Payment date: 18th April 2026 Dividend yield will be 1.1%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (15% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 12% per year over the past 6 years and payments have been stable during that time. EPS is expected to grow by 37% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Announcement • Dec 13
DongKook Pharmaceutical Co., Ltd. announces Annual dividend, payable on April 18, 2026 DongKook Pharmaceutical Co., Ltd. announced Annual dividend of KRW 200.0000 per share payable on April 18, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Valuation Update With 7 Day Price Move • Sep 11
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩19,750, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 13% over the past three years. New Risk • Aug 30
New minor risk - Financial data availability Less than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 19
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: ₩1,382 (up from ₩1,064 in FY 2023). Revenue: ₩812.2b (up 11% from FY 2023). Net income: ₩61.2b (up 30% from FY 2023). Profit margin: 7.5% (up from 6.5% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates by 1.3%. Revenue is forecast to grow 8.5% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Feb 14
DongKook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 21, 2025 DongKook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 21, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 715, yeongdong-daero, gangnam-gu, seoul South Korea New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company. New Risk • Dec 09
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company. Announcement • Oct 16
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:A086450) agreed to acquire 53.66% stake in Rebom Cosmetic Co.,Ltd. from Lee Kwangjeon for KRW 30.66 billion. DongKook Pharmaceutical Co., Ltd. (KOSDAQ:A086450) agreed to acquire 53.66% stake in Rebom Cosmetic Co.,Ltd. from Lee Kwangjeon for KRW 30.66 billion on October 15, 2024. A cash consideration of KRW 30.66 billion will be paid by DongKook Pharmaceutical Co., Ltd. As part of consideration, KRW 30.66 billion is paid towards common equity of Rebom Cosmetic Co.,Ltd. For the period ending December 31, 2023, Rebom Cosmetic Co.,Ltd. reported total revenue of KRW 22.47 billion and net income of KRW 2.73 billion. As of December 31, 2023, Rebom Cosmetic Co.,Ltd. reported total debt of KRW 9.59 billion and total assets of KRW 26.16 billion. The expected completion of the transaction is October 22, 2024. Major Estimate Revision • Apr 20
Consensus EPS estimates fall by 18%, revenue upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from ₩802.0m to ₩810.5m. EPS estimate fell from ₩1,513 to ₩1,241 per share. Net income forecast to grow 17% next year vs 16% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩24,000 unchanged from last update. Share price was steady at ₩16,060 over the past week. Reported Earnings • Mar 20
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: ₩1,073 (down from ₩1,203 in FY 2022). Revenue: ₩731.0b (up 11% from FY 2022). Net income: ₩47.2b (down 11% from FY 2022). Profit margin: 6.5% (down from 8.0% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 10%. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Price Target Changed • Jan 10
Price target increased by 7.5% to ₩21,500 Up from ₩20,000, the current price target is an average from 2 analysts. New target price is 18% above last closing price of ₩18,280. Stock is up 13% over the past year. The company is forecast to post earnings per share of ₩1,189 for next year compared to ₩1,203 last year. Upcoming Dividend • Dec 20
Upcoming dividend of ₩180 per share at 1.2% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Payout ratio is a comfortable 17% but the company is not cash flow positive. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (1.1%). Price Target Changed • Jul 21
Price target decreased by 9.1% to ₩20,000 Down from ₩22,000, the current price target is an average from 2 analysts. New target price is 46% above last closing price of ₩13,700. Stock is down 28% over the past year. The company is forecast to post earnings per share of ₩1,345 for next year compared to ₩1,203 last year. Upcoming Dividend • Dec 21
Upcoming dividend of ₩180 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Payout ratio is a comfortable 13% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (1.0%). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Price Target Changed • Oct 21
Price target decreased to ₩25,000 Down from ₩27,667, the current price target is an average from 3 analysts. New target price is 58% above last closing price of ₩15,850. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₩1,467 for next year compared to ₩1,146 last year. Price Target Changed • May 30
Price target increased to ₩29,000 Up from ₩26,500, the current price target is an average from 3 analysts. New target price is 32% above last closing price of ₩22,000. Stock is down 23% over the past year. The company is forecast to post earnings per share of ₩1,497 for next year compared to ₩1,146 last year. Price Target Changed • Apr 27
Price target decreased to ₩26,500 Down from ₩33,000, the current price target is an average from 2 analysts. New target price is 24% above last closing price of ₩21,450. Stock is down 25% over the past year. The company is forecast to post earnings per share of ₩1,487 for next year compared to ₩1,146 last year. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • Dec 22
Upcoming dividend of ₩180 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. Payout ratio is a comfortable 18% but the company is paying out more than the cash it is generating. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (2.4%). In line with average of industry peers (0.8%). Price Target Changed • Jul 08
Price target decreased to ₩26,000 Down from ₩30,500, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of ₩26,200. Stock is down 4.9% over the past year. Major Estimate Revision • May 21
Consensus EPS estimates increase to ₩1,701 The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from ₩605.0m to ₩634.7m. EPS estimate increased from ₩1,524 to ₩1,701 per share. Net income forecast to grow 38% next year vs 38% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩30,500 to ₩28,500. Share price was steady at ₩27,400 over the past week. Price Target Changed • May 08
Price target decreased to ₩30,500 Down from ₩35,000, the current price target is an average from 2 analysts. New target price is 9.5% above last closing price of ₩27,850. Stock is up 40% over the past year. Announcement • Feb 18
DongKook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021 DongKook Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021, at 10:00 Korea Standard Time. Location: Grand Auditorium, B1, Dongguk Building, 7 Teheran-ro 108-gil Seoul South Korea Is New 90 Day High Low • Jan 14
New 90-day high: ₩29,700 The company is up 18% from its price of ₩25,200 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩55,831 per share. Is New 90 Day High Low • Dec 21
New 90-day high: ₩28,750 The company is up 7.0% from its price of ₩26,750 on 22 September 2020. The South Korean market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩56,185 per share. Price Target Changed • Dec 17
Price target raised to ₩35,000 Up from ₩30,333, the current price target is an average from 2 analysts. The new target price is 24% above the current share price of ₩28,200. As of last close, the stock is up 59% over the past year. Is New 90 Day High Low • Oct 13
New 90-day low: ₩25,550 The company is down 5.0% from its price of ₩26,900 on 15 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩47,471 per share. Major Estimate Revision • Oct 10
Analysts update estimates The 2020 consensus earning per share (EPS) estimate was lowered from ₩1,517 to ₩1,110. Revenue estimate was approximately flat at ₩549.6m. Net income is expected to grow by 16% next year compared to 8.5% growth forecast for the Pharmaceuticals industry in South Korea. The consensus price target increased from ₩30,333 to ₩30,667. Share price is down by 1.3% to ₩27,000 over the past week. 
